ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2025
The ACE/lymphocyte ratio and CONUT score: Key predictors of extrapulmonary involvement and recurrence in sarcoidosis.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimExtrapulmonary involvement is associated with high morbidity and mortality in sarcoidosis. Sarcoidosis recurrence rates vary between 37-75% in the literature. In this study, we aimed to investigate the association of ACE/lymphocyte ratio and CONUT score with systemic involvement and recurrence in sarcoidosis.
methods156 adult patients diagnosed with sarcoidosis was conducted in this retrospective, single-center study between 01.09.2016 - 31.12.2021 in the pulmonology clinic of Sultan 2. Abdulhamid Han Training and Research Hospital in Istanbul/Türkiye. The ACE/lymphocyte ratio was calculated by dividing the serum ACE level by lymphocyte count. CONUT score was calculated according to serum albumin, lymphocyte count and total cholesterol levels.
resultsFifty (32%) patients had systemic involvement. In patients with systemic involvement, serum ACE and ACE/lymphocyte ratio were higher and lymphocytes were lower than those without systemic involvement (p<0.05). 24 (15.4%) patients had recurrence. Serum ACE and ACE/lymphocyte ratio were found to be higher in patients with recurrence compared to those without recurrence (p<0.05). There was no statistically significant difference between the groups in terms of CONUT score (p=0.232). In Spearmen's Rho correlation, systemic involvement and recurrence were positively correlated with ACE/lymphocyte ratio (p<0.05). In Binary Logistic Regression, ACE/lymphocyte ratio was not associated with recurrence and systemic involvement (p>0.05). In ROC curve analysis, the sensitivity, specificity and AUC of ACE/lymphocyte ratio in predicting systemic involvement were 78%, 39.8% and 0.644, respectively with a cut-off value of 19.55; and in predicting recurrence were 79.2%, 44.8% and 0.714, respectively with a cut-off value of 22.41.
conclusionsThe ACE/lymphocyte ratio, which was evaluated for the first time in the literature, may be used to predict extrapulmonary involvement, which can have high mortality and morbidity, as well as recurrence in post-treatment follow-up.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.